健择在难治性非霍奇金淋巴瘤治疗中的应用研究  

Clinical Applications of Gemcitabine in the Treatment of Refractory Non-Hodgkin's Lymphoma

作　　者：黄日平 马树东[1] 盛信秀[1] 罗荣城[1] 蔡红兵[1] 

机构地区：[1]第一军医大学南方医院肿瘤科,广州510515

出　　处：《肿瘤防治研究》2004年第3期166-167,共2页Cancer Research on Prevention and Treatment

摘　　要：目的　观察健择联合顺铂、强的松治疗难治性非霍奇金淋巴瘤的近期疗效。方法　健择10 0 0mg/m2 ,静滴 ,d1,8;顺铂 2 5mg/m2 ,静滴 ,d1～ 3 ;强的松 6 0mg/m2 ,口服 ,d1～ 5。以 3～ 4周为 1周期 ,每例患者至少连用 3个周期。结果　全组 10例病人中 ,CR 2例 ,PR 5例 ,总有效率 70 %。 4例具有B类症状患者中 ,2例症状消失 ,1例明显改善 ,1例无改善。毒副反应主要是轻度的胃肠道反应和少数患者出现Ⅲ级以上骨髓抑制。结论　健择联合顺铂、强的松治疗难治性非霍奇金淋巴瘤有较好的近期疗效 ,其毒副反应可耐受 ,是值得临床进一步验证的补救性化疗方案。Objective To study the effects of gemcitabine combined with cisplatine and predinisone in the treatment of refractory Non-Hodgkin's Lymphoma(NHL). Methods 10 patients with refractory NHL were treated with gemcitabine, 1000mg/m 2,VD,d_ 1,8;cisplatine, 25mg/m 2,VD,d_ 1～3; and prednisone, 60mg/m 2, po,d_ 1～5; every cycle(3～4 weeks). All patients received at least three cycles of chemotherapy. Results There were 2 cases of CR, 5 cases of PR and the total response rate was 70%. Of the 4 patients who suffered from type B symptoms,2 showed the complete alleviatien of the type B symptoms,1 showed the obvious alleviation and 1 showed no alleviation.The main side effects include mild myelosuppression and gastrointestinal effects. Conclusion As a rescue chemotherapy eutic treatment to NHL,the regimen of gemcitabine combined with cisplatine and predinisone could make ideal short-term therapeutic effects. Most of the patients tolerated haematological toxicity well.

关 键 词：健择 难治性非霍奇金淋巴瘤 化疗 近期疗效 阿糖胞苷类似物 毒副反应 

分 类 号：R979.1[医药卫生—药品] R733[医药卫生—药学]